Enzo Biochem will announce its third Q

0

Conference call and webcast scheduled for June 9, 2022, 4:30 p.m. ET

NEW YORK, NY, June 02, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (:ENZ), a leading bioscience and diagnostics company, today announced that it will report financial results for the third quarter 2022 on Thursday, June 9, 2022, after market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time.

Thursday June 9e @ 4:30 p.m. ET
Domestic: 877-407-0792
International: 201-689-8263
Conference ID: 13730182

Webcast: Registration Link — Click Here

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that offer many advantages over previous standards. A global company, Enzo Biochem uses cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing healthcare needs of today and tomorrow. Enzo Biochem’s products and technologies are supported by a broad and deep intellectual property portfolio, with patent coverage on a number of key enabling technologies.

For more information, please visit Enzo.com or follow Enzo Biochem on Twitter and LinkedIn.

Forward-looking statements
Except for historical information, the matters discussed in this release may be deemed “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding the intention, belief or current expectations of the Company and its management, including those relating to cash flow, gross margins, revenues and expenses which depend on a number of factors beyond the Company’s control, including, but not limited to, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation and general trade conditions. See the risk factors in the company’s Form 10-K for the fiscal year ended July 31, 2021. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. . The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

###

Contact:

For Enzo Biochem, Inc.

David Banc, Chief Financial Officer
212-583-0100
[email protected]

Investors:

Chris Calabrian
LifeSci Advisors, LLC
917-680-5608
[email protected]

Media:

Lynn Granito
Berry & Company Public Relations
212-253-8881
[email protected]

Enzo-Biochem-Inc-.png

Share.

Comments are closed.